hVIVO successfully completes RSV challenge study in Older Adults   London, UK – 6 August 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral challenge, announces the successful...

Location: Queen Mary Innovation Centre, 5 Walden Street, London, E1 2EF Date: 13th February Time: 14.00 – 19.30 The track record of success delivered by London’s academic institutions, their commercial teams and the spin out companies they have collectively created...

hVIVO has signed new contracts with a leading global biopharmaceutical company   ▪ Contracted for two respiratory syncytial virus (RSV) human challenge studies ▪ Studies projected to deliver a total of c.£9m in revenue from Q4’18 through to end of 2019 ▪...

Queen Mary joins London cancer research powerhouse   The city of London will be transformed into a world leading hub for cancer biotherapeutics research and treatment, with a new £14 million investment from Cancer Research UK, announced today.   The new Cancer...

hVIVO plc (AIM: HVO), the pioneer of human disease models, is delighted to announce that the Company’s landmark asthma stratification initiative is now underway, with the first volunteer inoculated with human rhinovirus (HRV) at hVIVO’s London based...

Immuno-Oncology Investment Forum Immuno-Oncology (IO) has been one of, if not the, hottest area in biopharma over recent years. High profile financings, approvals and challenges have emerged and competition for new innovative programmes is fierce. To complement the...

Location: Queen Mary Innovation Centre, 5 Walden Street, London, E1 2EF Supported by: Hume Brophy Date: 14th April Time: 14.00 – 19.30 Programme (subject to change) 14.00 Registration and refreshments 14.30 Welcome 14.45 Session 1: Investing in Technology in...

Retroscreen Virology is proud to announce corporate name change to hVIVO to reflect pioneering efforts in human disease models. Revolutionising drug development through human studies Retroscreen Virology, a leading life sciences human disease model company, is...

What does London’s Life Sciences Sector want from the next Mayor? The first London Mayor, Ken Livingstone, used the London Development Agency as a delivery vehicle to create “BioLondon” as a brand and activity to promote London’s strengths and coordinate the...

Graphene has been hailed as a new wonder material, yet since its discovery at Manchester University in 2004 the UK accounts for less than 1% of total graphene patents filed worldwide. To compete on the international stage, we need a more robust commitment from the...